Overview
Humanin is a 21-amino acid mitochondrial-derived peptide (MDP) first identified as a neuroprotective factor against Alzheimer's disease-related neuronal death. Encoded within the 16S ribosomal RNA gene of mitochondrial DNA, humanin has emerged as a compelling therapeutic candidate for multiple age-related conditions and metabolic dysfunction. What makes humanin particularly interesting is that circulating levels naturally decline with age, positioning it as both a biomarker of aging and a potential intervention target.
Unlike traditional pharmaceuticals, humanin operates at the intersection of cellular survival, metabolic regulation, and mitochondrial function. It has attracted significant research interest spanning neuroprotection, cardiovascular health, insulin sensitivity, metabolic disease, and longevity—domains central to healthy aging. However, it's important to note that humanin is not approved as a pharmaceutical in any jurisdiction and remains available only as a research peptide, with quality and purity heavily dependent on vendor reliability.
How It Works: Mechanism of Action
Humanin exerts its protective effects through multiple interconnected mechanisms:
Primary Receptor Signaling
Humanin binds to a trimeric receptor complex composed of CNTFR, WSX-1, and gp130, activating downstream JAK2/STAT3 and PI3K/Akt signaling pathways. These pathways suppress apoptosis (programmed cell death) and promote cell survival—a mechanism particularly relevant for neurons and cardiac tissue under stress.
Direct Anti-Apoptotic Action
Beyond receptor binding, humanin acts intracellularly by binding directly to BAX, a pro-apoptotic protein. By preventing BAX from translocating to the mitochondrial membrane, humanin blocks cytochrome c release and inhibits the intrinsic apoptotic cascade. This dual mechanism—both extracellular signaling and intracellular protein interaction—makes it a uniquely multifaceted cytoprotective agent.
Metabolic Regulation
Humanin functions as an insulin sensitizer through FPRL1/FPR2 receptor interactions, modulating hepatic glucose output and improving peripheral glucose uptake. This metabolic action contributes to both its cytoprotective effects and potential benefits for metabolic health and body composition.
Evidence by Health Goal
The following sections organize research findings by health domain, with each goal assigned an evidence tier reflecting the strength of current evidence:
Tier 1 = Insufficient or absent human evidence Tier 2 = Promising animal/mechanistic evidence with limited human data Tier 3 = Probable human effects based on observational studies; no definitive RCT proof
Neuroprotection & Cognition (Tier 3)
Humanin shows probable neuroprotective effects based on multiple human observational studies and consistent animal research, though efficacy remains unproven in living human subjects with validated cognitive assessments.
In humans with obstructive sleep apnea (OSA) without dementia (n=268), neuron-derived exosome humanin levels were significantly elevated in the OSA+mild cognitive impairment (MCI) group compared to OSA without MCI and control groups. Critically, CPAP therapy reduced humanin levels after one year, and this reduction correlated with cognitive improvement—suggesting humanin may serve as a dynamic biomarker of neuroprotection.
In aged mice, humanin administration improved cognition in vivo and prevented age-related cognitive decline, with neuroprotective effects also demonstrated in human cell cultures. However, only four human RCTs exist examining humanin, and none specifically measured cognitive outcomes in living subjects using validated cognitive assessments.
Cardiovascular Health & Heart Function (Tier 3)
Humanin shows probable cardioprotective effects in human studies, with lower circulating levels independently associated with coronary artery disease and major adverse cardiac events (MACE).
In a human observational study (n=327), circulating humanin levels were 57% lower in myocardial infarction (MI) patients compared to controls (67.17 ± 24.35 pg/mL vs. 157.77 ± 99.93 pg/mL; p<0.05). Lower humanin remained an independent risk factor for MI even after adjusting for other variables.
In angina patients, humanin levels were significantly lower (124.22 ± 63.02 pg/mL) compared to controls (157.77 ± 99.93 pg/mL; p<0.05), and circulating humanin predicted major adverse cardiac events. However, evidence relies primarily on observational studies, and RCT data remains limited with inconsistent findings in some contexts.
Metabolic Health & Fat Loss (Tier 2)
Humanin shows metabolic benefits for fat loss and insulin sensitivity in animal models, though no human clinical trials confirm efficacy in humans.
The HNG humanin analog (S14G variant) decreased body weight gain, reduced visceral fat, and decreased hepatic triglyceride accumulation in high-fat diet-fed mice. These effects were centrally mediated via the vagus nerve, suggesting a brain-body pathway for metabolic regulation.
MOTS-c, another humanin analog, prevented age-dependent and high-fat-diet-induced obesity and insulin resistance in mice, with skeletal muscle identified as the primary target organ. In mice on a high-fat diet, HNG reduced hepatic triglyceride accumulation through increased hepatic MTTP activity and triglyceride secretion.
Muscle Function & Growth (Tier 2)
Humanin shows promise for muscle growth through autophagy induction and mitochondrial function improvement, though no human RCTs exist specifically measuring muscle growth as an endpoint.
Humanin administration increased autophagy-related gene expression and lowered misfolded protein accumulation in mouse skeletal muscle. In C. elegans models, humanin-induced autophagy was critical for lifespan extension and contributed to improved skeletal function.
In humans, resistance training for 12 weeks increased skeletal muscle humanin protein levels by 35% in men with impaired glucose metabolism (n=55), suggesting that humanin may be upregulated during muscle adaptation. However, direct evidence that supplemental humanin improves muscle growth in humans is absent.
Energy & Mitochondrial Function (Tier 2)
Humanin shows promise for energy metabolism and mitochondrial function through mechanistic studies and animal models, though rigorous human RCT evidence is lacking.
Humanin induces autophagy and improves skeletal muscle function in mice, with upregulation of autophagy-related genes and reduced misfolded protein accumulation. The HNG analog improves metabolic healthspan parameters and reduces inflammatory markers in middle-aged mice treated twice weekly.
In humans, acute endurance exercise (45 minutes at 70% VO2max) significantly elevated circulating humanin (n=10), though humanin levels showed no correlation to fitness outcomes including VO2max, leg strength, or mitochondrial DNA copy number—suggesting humanin may be a responsive biomarker without direct performance effects.
Anti-Inflammatory Effects (Tier 2)
Humanin shows anti-inflammatory effects in multiple animal and cell culture models, with one small human RCT demonstrating benefits when combined with exercise and astaxanthin.
In 90 women with type 2 diabetes, combined exercise plus astaxanthin (which increased humanin levels) reduced inflammatory markers, with humanin levels increasing significantly in both the control training (CT) and CT+supplement (S) groups (p<0.05). The study measured changes in inflammatory miRNAs, upregulating anti-inflammatory miRNA-126-3p and miRNA-146a while downregulating pro-inflammatory miRNA-122.
In an acute peritonitis mouse model, preventive humanin administration reduced leukocyte infiltration and pro-inflammatory cytokine secretion while promoting early acquisition of pro-resolving macrophage phenotype—suggesting humanin modulates immune resolution.
Joint & Bone Health (Tier 2)
Humanin shows promise for joint health through anti-apoptotic and anti-inflammatory mechanisms in animal models, though no human clinical trials have been conducted.
HNGF6A, a humanin variant, protected MC3T3-E1 osteoblasts from hydrogen peroxide-induced apoptosis and promoted osteogenic differentiation by downregulating Circ_0001843 and upregulating miR-214 in vitro.
HNG (0.1 mg/kg/day) combined with dexamethasone reduced TUNEL-positive (apoptotic) chondrocytes in both articular and growth plate cartilage in collagen-induced arthritis mice without interfering with anti-inflammatory effects.
Injury Recovery (Tier 2)
Humanin shows promise for injury recovery through mitochondrial protection and anti-inflammatory mechanisms, though no human RCTs demonstrate clinical efficacy for this indication.
In mice with intracerebral hemorrhage, intravenously administered humanin penetrated brain tissue, reduced neurological deficits, and improved hematoma clearance.
Humanin pretreatment in cultured rat neurons exposed to NMDA (excitotoxic) toxicity increased mitochondrial succinate dehydrogenase activity and membrane potential while reducing reactive oxygen species and nitric oxide production—key markers of neuronal protection.
Liver Health (Tier 2)
Humanin shows plausible hepatoprotective mechanisms in animal models and theoretical benefits for liver metabolism, though no human clinical trials demonstrate efficacy.
The humanin analog HNG decreased hepatic triglyceride accumulation in high-fat diet-fed mice through increased hepatic MTTP activity and triglyceride secretion. HNG also reduced body weight gain and visceral fat in mice on high-fat diet, with these effects mediated through central nervous system pathways.
Immune Support (Tier 2)
Humanin shows plausible anti-inflammatory and immune-modulatory effects primarily in animal models, with limited human evidence.
In the human RCT of 90 women with type 2 diabetes, combined training plus astaxanthin increased humanin levels significantly (p<0.05) and upregulated anti-inflammatory miRNAs while downregulating pro-inflammatory variants.
In mice with acute peritonitis, humanin administration reduced leukocyte infiltration and pro-inflammatory cytokine secretion, promoting resolution of inflammation.
Reproductive & Sexual Health (Tier 2)
Humanin shows promise for reproductive health based on consistent animal studies and one human observational study, though efficacy in humans remains unproven.
In female mice with chemotherapy-induced ovarian damage, HNG increased primordial follicles (P=0.044), improved oocyte quality (P=0.009), reduced abnormal ovulated oocytes (P=0.002), and improved fertility with litter size increasing from 4.6±1.1 to 6.2±0.8 (P=0.029).
In male mice with prepubertal chemotherapy exposure, HNG protected spermatogenic function and testicular tissue, with transcriptomic evidence of altered expression in genes related to male reproductive function.
Longevity & Healthspan (Tier 2)
Humanin shows plausible mechanisms for longevity extension in animal models with preliminary observational data in humans, though no human RCTs have demonstrated proven efficacy for extending lifespan or healthspan.
In C. elegans, humanin overexpression increased lifespan in a daf-16/Foxo-dependent manner. Middle-aged mice treated twice weekly with HNG analog showed improved metabolic healthspan parameters and reduced inflammatory markers.
Athletic Performance (Tier 2)
Humanin levels increase acutely in response to exercise in humans, particularly endurance exercise, though no human RCTs have demonstrated that supplementation directly improves performance.
Acute endurance exercise significantly elevated circulating humanin in humans, but levels showed no correlation to fitness outcomes including VO2max, leg strength, or mitochondrial DNA copy number—indicating humanin is a responsive biomarker rather than a direct performance determinant.
Hormonal Balance (Tier 2)
Humanin shows plausible effects on reproductive hormones and metabolic markers in animal models and small human observational studies, though no human RCTs prove efficacy.
In humans with polycystic ovary syndrome (PCOS), humanin concentrations in follicular fluid were significantly lower in PCOS patients with insulin resistance versus those without, suggesting a potential role in reproductive-metabolic health.
Mood & Stress (Tier 1)
Humanin has not been studied for mood or stress in humans. All mechanistic evidence comes from reviews describing anti-inflammatory properties, but no clinical efficacy for mood or psychological outcomes has been demonstrated.
Sleep (Tier 1)
Humanin has not been demonstrated to improve sleep outcomes in any study. Two human observational studies mention humanin only as a biomarker altered in sleep disorders—not as a therapeutic intervention.
Gut Health (Tier 1)
Humanin is mentioned only in review articles discussing broader topics (colorectal cancer biomarkers and lifespan regulation), with no direct evidence of efficacy for gut health demonstrated in any study.